💨 Abstract

Akums Drugs and Pharmaceuticals Ltd. reported a 12% increase in Adjusted EBITDA for Q3 2024. The robust performance was driven by better profitability in the core CDMO segment and improved product mix. API EBITDA losses reduced significantly, but cephalosporin API prices remained low. The branded formulation business performed well domestically and internationally.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖